Institution/Company	Date	Partner	Terms
University of Pennsylvania	August 2012	Novartis	Undisclosed
Celgene	March 2013	Bluebird Bio, Baylor College of Medicine	Unspecified upfront payment plus up to $225 million per product in option fees and milestone payments
Cellectis	June 2014	Pfizer	$80 million upfront plus up to $185 million per product and royalties
Cellectis	January 2015	Ohio State University	Undisclosed
Kite Pharma	January 2015	Amgen	$60 million upfront and up to $525 million per product in milestone payments, plus royalties on sales and IP licensing
Md Anderson	January 2015	Ziopharm, Intrexon	$100 million in stock and $15–20 million/year for 3 years

A new report by EP Vantage, the editorial team at life science market intelligence firm Evaluate Ltd, notes that while investor enthusiasm for this sector is unlikely to diminish anytime soon, “there may be hidden dangers” for those in it to make a big return. “CAR T therapy looks like it’s becoming little short of a revolution in the treatment of some cancer types, but numerous risks are being lost in the hype,” writes report author Jacob Plieth, a biochemist by training. “It is important to appreciate the risks as well as the opportunities to have a clear understanding of the market potential of these therapies and their developers.”